Preliminary results from a groundbreaking trial, HPTN 052, were released on May 12, 2011. The trial demonstrated that starting ART in HIV-infected individuals substantially protected their HIV-uninfected sexual partners from acquiring HIV infection, with a 96% reduction in risk of HIV transmission.

ICAP Director Wafaa El-Sadr has weighed in on the implications of this study in recent news coverage, including that of NPR, New York Times, and AFP. On June 2, she will deliver a webinar presentation that will highlight what is known about use of ART for prevention and discuss implications of the findings for confronting the HIV epidemic.